| Followers | 11 |
| Posts | 1963 |
| Boards Moderated | 0 |
| Alias Born | 04/16/2024 |
Friday, December 06, 2024 12:31:27 PM
Congrats - you are right i go by charts too...
but not when the PRs make me want to run in the opposite direction.
Seen to many of these cons pinged up to unload shares.
but not when the PRs make me want to run in the opposite direction.
Seen to many of these cons pinged up to unload shares.
Recent TELO News
- Form 8-K - Current report • Edgar (US Regulatory) • 03/31/2026 01:15:16 PM
- Telomir Pharmaceuticals Submits IND to FDA for Telomir-1 (Telomir-Zn) in Advanced and Metastatic Triple-Negative Breast Cancer • ACCESS Newswire • 03/31/2026 12:00:00 PM
- Form 8-K - Current report • Edgar (US Regulatory) • 03/31/2026 11:00:09 AM
- Form 8-K - Current report • Edgar (US Regulatory) • 03/27/2026 09:00:09 PM
- Form 10-K - Annual report [Section 13 and 15(d), not S-K Item 405] • Edgar (US Regulatory) • 03/17/2026 09:28:20 PM
- Form DEFM14A - Definitive proxy statement relating to merger or acquisition • Edgar (US Regulatory) • 02/19/2026 10:16:10 PM
- Form DEFA14A - Additional definitive proxy soliciting materials and Rule 14(a)(12) material • Edgar (US Regulatory) • 02/19/2026 10:12:17 PM
- Form 8-K - Current report • Edgar (US Regulatory) • 02/17/2026 01:00:48 PM
- Telomir Pharmaceuticals Demonstrates Broad Tumor Cell Mortality in Human Triple-Negative Breast Cancer Models • ACCESS Newswire • 02/17/2026 01:00:00 PM
- Telomir Pharmaceuticals Reports New Data Supporting an Epigenetic Modulation Mechanism Implicated in Cancer and Aging • ACCESS Newswire • 02/05/2026 01:00:00 PM
- Form 8-K - Current report • Edgar (US Regulatory) • 02/05/2026 12:30:43 PM
- Form PRER14A - Preliminary Proxy Soliciting materials • Edgar (US Regulatory) • 01/23/2026 10:04:58 PM
- Form 8-K - Current report • Edgar (US Regulatory) • 01/05/2026 01:00:54 PM
- Telomir Pharmaceuticals Announces Telomir-1 Significantly Reduced Tumor Growth and Metastases in Aggressive Triple-Negative Breast Cancer Animal Models • ACCESS Newswire • 01/05/2026 01:00:00 PM
- Telomir Pharmaceuticals Reports Favorable IND-Enabling GLP Safety Results for Telomir-1 Supporting First-in-Human Clinical Development • ACCESS Newswire • 12/18/2025 12:30:00 PM
- Form 8-K - Current report • Edgar (US Regulatory) • 12/17/2025 09:01:45 PM
- Form PRER14A - Preliminary Proxy Soliciting materials • Edgar (US Regulatory) • 11/28/2025 09:59:00 PM
- Telomir Pharmaceuticals Reports New Data Showing Telomir-1 Significantly Reduces PSA Levels in Human Prostate Cancer Cells • ACCESS Newswire • 11/25/2025 01:00:00 PM
- Form 8-K - Current report • Edgar (US Regulatory) • 11/24/2025 09:01:40 PM
- Telomir Pharmaceuticals Announces Telomir-1 Kills Aggressive Human Leukemia Cells • ACCESS Newswire • 11/21/2025 12:30:00 PM
- Form 8-K - Current report • Edgar (US Regulatory) • 11/20/2025 10:15:27 PM
- Form PREM14A - Preliminary proxy statements relating to merger or acquisition • Edgar (US Regulatory) • 11/20/2025 09:16:45 PM
- Form 8-K - Current report • Edgar (US Regulatory) • 11/20/2025 09:01:58 PM
- Telomir Pharmaceuticals Reports Telomir-1 Outperforms FDA-Approved Gold-Standard Iron Chelator Deferoxamine (DFO) in Reducing Intracellular Iron in a Human Cell Line • ACCESS Newswire • 11/12/2025 01:00:00 PM
- Form 8-K - Current report • Edgar (US Regulatory) • 11/12/2025 12:00:56 PM
